Enhancing the Function of CD34+ Cells by Targeting Plasminogen Activator Inhibitor-1

Previously, we showed that transient inhibition of TGF- β1 resulted in correction of key aspects of diabetes-induced CD34+ cell dysfunction. In this report, we examine the effect of transient inhibition of plasminogen activator inhibitor-1 (PAI-1), a major gene target of TGF-β1 activation. Using gene array studies, we examined CD34+ cells isolated from a cohort of longstanding diabetic individuals, free of microvascular complications despite suboptimal glycemic control, and found that the cells exhibited reduced transcripts of both TGF-β1 and PAI-1 compared to age, sex, and degree of glycemic control-matched diabetic individuals with microvascular complications. CD34+ cells from diabetic subjects with microvascular complications consistently exhibited higher PAI-1 mRNA than age-matched non-diabetic controls. TGF- β1 phosphorodiamidate morpholino oligo (PMO) reduced PAI-1 mRNA in diabetic (p<0.01) and non-diabetic (p=0.05) CD34+ cells. To reduce PAI-1 in human CD34+ cells, we utilized PAI-1 siRNA, lentivirus expressing PAI-1 shRNA or PAI-1 PMO. We found that inhibition of PAI-1 promoted CD34+ cell proliferation and migration in vitro, likely through increased PI3(K) activity and increased cGMP production. Using a retinal ischemia reperfusion injury model in mice, we observed that recruitment of diabetic CD34+ cells to injured acellular retinal capillaries was greater after PAI-1-PMO treatment compared with control PMO-treated cells. Targeting PAI-1 offers a promising therapeutic strategy for restoring vascular reparative function in defective diabetic progenitors.

[1]  Dexter Kozen,et al.  New , 2020, MFPS.

[2]  M. Marescotti,et al.  Diabetes Impairs Stem Cell and Proangiogenic Cell Mobilization in Humans , 2013, Diabetes Care.

[3]  Alan W. Stitt,et al.  Activation of the ACE2/Angiotensin-(1–7)/Mas Receptor Axis Enhances the Reparative Function of Dysfunctional Diabetic Endothelial Progenitors , 2013, Diabetes.

[4]  T. Henry,et al.  Intramyocardial, Autologous CD34+ Cell Therapy for Refractory Angina , 2011, Circulation research.

[5]  Paul J. Higgins,et al.  PAI-1: An Integrator of Cell Signaling and Migration , 2011, International journal of cell biology.

[6]  M. Grant,et al.  Blockade of NADPH oxidase restores vasoreparative function in diabetic CD34+ cells. , 2011, Investigative ophthalmology & visual science.

[7]  C. Pepine,et al.  Transient Inhibition of Transforming Growth Factor-β1 in Human Diabetic CD34+ Cells Enhances Vascular Reparative Functions , 2010, Diabetes.

[8]  M. Grant,et al.  Inhibition of NADPH oxidase restores vasoreparative function in diabetic CD34+ cells , 2010 .

[9]  L. Ye,et al.  Therapeutic angiogenesis by transplantation of human embryonic stem cell-derived CD133+ endothelial progenitor cells for cardiac repair. , 2010, Regenerative medicine.

[10]  M. Boulton,et al.  Diabetic retinopathy is associated with bone marrow neuropathy and a depressed peripheral clock , 2009, The Journal of experimental medicine.

[11]  P. McGuire,et al.  Plasminogen activator inhibitor-1 (PAI-1) facilitates retinal angiogenesis in a model of oxygen-induced retinopathy. , 2009, Investigative ophthalmology & visual science.

[12]  Qingbo Xu,et al.  Vascular repair by endothelial progenitor cells. , 2008, Cardiovascular research.

[13]  Po-Len Liu,et al.  High Glucose Impairs Early and Late Endothelial Progenitor Cells by Modifying Nitric Oxide–Related but Not Oxidative Stress–Mediated Mechanisms , 2007, Diabetes.

[14]  D. Buerk,et al.  Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. , 2007, The Journal of clinical investigation.

[15]  N. Sengupta,et al.  Ischemic Vascular Damage Can Be Repaired by Healthy, but Not Diabetic, Endothelial Progenitor Cells , 2007, Diabetes.

[16]  Chao-Yung Wang,et al.  Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells. , 2007, American journal of physiology. Heart and circulatory physiology.

[17]  P. Galuppo,et al.  Endothelial Nitric Oxide Synthase Uncoupling Impairs Endothelial Progenitor Cell Mobilization and Function in Diabetes , 2007, Diabetes.

[18]  A. Avogaro,et al.  Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk. , 2006, European heart journal.

[19]  R. Bernards,et al.  Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence , 2006, Nature Cell Biology.

[20]  P. Dentelli,et al.  p53 Mediates the Accelerated Onset of Senescence of Endothelial Progenitor Cells in Diabetes* , 2006, Journal of Biological Chemistry.

[21]  Shawdee Eshghi,et al.  Down-regulation of Plasminogen Activator Inhibitor 1 Expression Promotes Myocardial Neovascularization by Bone Marrow Progenitors , 2004, The Journal of experimental medicine.

[22]  R. Czekay,et al.  The Low Density Lipoprotein Receptor-related Protein Is a Motogenic Receptor for Plasminogen Activator Inhibitor-1* , 2004, Journal of Biological Chemistry.

[23]  C. Heeschen,et al.  Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells , 2003, Nature Medicine.

[24]  M. Urban,et al.  New atherosclerosis risk factors in obese, hypertensive and diabetic children and adolescents. , 2003, Atherosclerosis.

[25]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[26]  G. Gurtner,et al.  Human Endothelial Progenitor Cells From Type II Diabetics Exhibit Impaired Proliferation, Adhesion, and Incorporation Into Vascular Structures , 2002, Circulation.

[27]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[28]  Peter Hufnagl,et al.  Plasminogen activator inhibitor 1: physiological and pathophysiological roles. , 2002, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.

[29]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[30]  M. Grant,et al.  Plasminogen activator inhibitor (PAI)-1 overexpression in retinal microvessels of PAI-1 transgenic mice. , 2000, Investigative ophthalmology & visual science.

[31]  M. Kurabayashi,et al.  Hypoxia induces transcription of the plasminogen activator inhibitor-1 gene through genistein-sensitive tyrosine kinase pathways in vascular endothelial cells. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[32]  E. Kandel,et al.  The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. , 1999, Experimental cell research.

[33]  E. Dejuan,et al.  Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. , 1999, Investigative ophthalmology & visual science.

[34]  W. Knowler,et al.  Diabetic Retinopathy, Promoter (4G/5G) Polymorphism of PAI-1 Gene, and PAI-1 Activity in Pima Indians With Type 2 Diabetes , 1997, Diabetes Care.

[35]  M. Grant,et al.  Plasminogen activator inhibitor-1 overexpression in nonproliferative diabetic retinopathy. , 1996, Experimental eye research.

[36]  D. Purich,et al.  Carbon Monoxide and Nitric Oxide Mediate Cytoskeletal Reorganization in Microvascular Cells via Vasodilator – Stimulated Phosphoprotein ( VASP ) Phosphorylation : Evidence for Blunted Responsiveness in Diabetes , 2008 .

[37]  B. Gong,et al.  Retinal ischemia and reperfusion causes capillary degeneration: similarities to diabetes. , 2007, Investigative ophthalmology & visual science.

[38]  R. Tran-Son-Tay,et al.  Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. , 2006, Diabetes.

[39]  Frank J T Staal,et al.  Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. , 2004, Diabetes.

[40]  G. Pellegrini,et al.  Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type 1 in the rat , 2001, Acta Diabetologica.